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Abstract
Background: Tumour samples containing distinct sub-populations of cancer and normal cells present challenges in
the development of reproducible biomarkers, as these biomarkers are based on bulk signals from mixed tumour
profiles. ISOpure is the only mRNA computational purification method to date that does not require a paired
tumour-normal sample, provides a personalized cancer profile for each patient, and has been tested on clinical data.
Replacing mixed tumour profiles with ISOpure-preprocessed cancer profiles led to better prognostic gene signatures
for lung and prostate cancer.
Results: To simplify the integration of ISOpure into standard R-based bioinformatics analysis pipelines, the algorithm
has been implemented as an R package. The ISOpureR package performs analogously to the original code in
estimating the fraction of cancer cells and the patient cancer mRNA abundance profile from tumour samples in four
cancer datasets.
Conclusions: The ISOpureR package estimates the fraction of cancer cells and personalized patient cancer mRNA
abundance profile from a mixed tumour profile. This open-source R implementation enables integration into existing
computational pipelines, as well as easy testing, modification and extension of the model.
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Background
Tumour heterogeneity provides both challenges and
opportunities in the development of cancer biomarkers.
Tumours are mixed populations of multiple cell-
types. Currently, the molecular profiles of interest –
those of cancer cells or of distinct sub-populations of
cancer cells – are blurred by the mixed signal from all
cell types in a sample [1,2]. However, characterizing the
heterogeneity of a patient’s tumour by identifying the
sub-populations present, along with their proportions
and molecular profiles, would provide a personalized
cancer “fingerprint” that captures both cell-centred and
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whole-system information, opening up opportunities for
targeted treatment [3,4]. The methods described in this
article apply to mRNA expression data rather than to to
DNA data (point mutations and copy number changes),
which require other approaches [5-8].
As a first step, it is important to consider the two-
population problem of normal and cancer cells. Even
small fractions of contaminating normal cells can intro-
duce noise in gene signatures [9,10], motivating the search
for methods to deconvolve a mixed tumour profile by
estimating the fraction of cancer cells and providing a per-
sonalized, purifiedmRNA abundance profile of the cancer
cells.
Physical approaches for sample separation, such as laser
capture micro-dissection [11] are costly, time-intensive,
not always available and may degrade samples. There-
fore, computational approaches to purification of tumour
molecular profiles have become increasingly important.
© 2015 Anghel et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
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Table 1 and Additional file 1 summarize the different
methods currently available for deconvolvingmRNA data.
Classical methods of profile deconvolution assume that
a mixed profile is a linear combination of a predeter-
mined number of pure constituent profiles. Written in
matrix form, the measured, mixed profiles B are a product
of A, a matrix of gene expression profiles of each con-
stituent, weighted by the fractions X of each cell type in
the mixture:
AX = B. (1)
Equivalently, some algorithms start with the transpose of
this equation. Different algorithms use different meth-
ods of deconvolution. Some assume that the fractions,
X, are known [12-17]. Others use gene expression pro-
files [18], signatures [19-22] or markers [23-26] of the
constituent profiles to recover X, and sometimes the
expression profiles of other genes in the constituents
[23]. (A gene marker is a set of genes assumed to be
expressed solely in one cell subtype and in no other
[4,27,28].) These approaches are limited in uncovering
patient-specific variation in cancer, as they assume that
all tumour profiles are mixtures of a small number of the
same constituents. In addition, the expression data may be
log-transformed [13,16], leading to a possible bias in the
reconstruction of mixed tissue samples from constituent
profiles [29].
Another approach to estimate both fraction of cancer
content as well as patient-specific cancer profiles requires
a matched normal profile for each patient [30,31]. In this
case the normal profile is “electronically subtracted” from
the bulk tumour profile. However, a matched normal pro-
file may not always be available in existing datasets and
may be difficult to obtain clinically. Furthermore, due to
the biological variability of normal tissue, the provided
normal profile may not match that of the tissue in the
tumour sample.
Two algorithms, DeMix [32] and ISOpure [33] present
statistical approaches for deconvolution of mixed tumour
profiles given a set of unmatched normal samples. Cancer
biomarkers generated from prostate and non-small cell
lung cancer data purified using ISOpure were more effec-
tive at predicting survival relative to those generated using
unpurified profiles [33].
Overview of ISOpure
In the following, we will use the term ‘ISOpure’ to refer
to the algorithm in general, and ISOpureR to refer to the
R package implementation. The next two sections will
describe the statistical model and the algorithm in more
detail, but we begin by providing a brief overview and
example.
For the applications discussed here, the ISOpure algo-
rithm is applied to microarray mRNA abundance data.
The inputs to the model must be normalized (but not log-
transformed) expression profiles. The following two sets
of inputs are required: tumour mRNA abundance pro-
files, of the same cancer sub-type; and normal (i.e. healthy)
mRNA abundance profiles, from the same tissue as the
tumour.
The algorithm runs in two steps.
1. Cancer Profile Estimation (CPE). This step
estimates and outputs an average cancer profile as
well as a fraction of cancer in each tumour sample.
2. Patient Profile Estimation (PPE). This step
estimates and outputs a cancer profile for each
patient.These profiles are all similar to the average
cancer profile, but contain patient-specific variations.
The estimated cancer fraction for each tumour
sample is fixed at the value calculated in the CPE step.
To run these two steps using ISOpureR, it suf-
fices to apply the two functions ISOpure.step1.CPE
and ISOpure.step2.PPE. The input expression data
should be in matrix form, with samples along the columns
and transcripts/features along the rows.
# For reproducible results, set the random
number generator seed set.seed(123);
# Run ISOpureR Step 1 - Cancer Profile
Estimation ISOpureS1model <- ISOpure.step1.
CPE(
tumour.expression.data,
normal.expression.data
);
# For reproducible results, set the random
seed set.seed(456);
# Run ISOpureR Step 2 - Patient Profile
Estimation ISOpureS2model <- ISOpure.step2.
PPE(
tumour.expression.data,
normal.expression.data,
ISOpureS1model
);
The vector ISOpureS1model$alphapurities pro-
duced by the first step contains the proportion of
cancer for each patient. The matrix ISOpureS2model
$cc_cancerprofiles produced by the second step
contains the patient-specific profiles, rescaled to be of
the same scale as the tumour expression data. That is,
these profiles are estimated as probabilities within the
algorithm, but are scaled to represent microarray signal
intensity data. A detailed example is given in Section 3
of the ISOpureR package vignette, included as Additional
file 2.
In the statistical and algorithm descriptions of ISOpure,
the notation tn describes the matrix of tumour profiles,
where the index n denotes the n-th patient. The fractions
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Table 1 An overview of computational deconvolution algorithms for RNA profiles
Method Ref. Input Output Clinical data? Availability
Prop. Expr. Individual Cancer Normal blood Other R CellMix MATLAB Other
profile
ISOpure (Quon) [33] tumour & unmatched normal      
DeMix (Ahn) [32] tumour & unmatched normal    
Clarke [30] paired mixed & pure profiles   
Gosink [31] mixed profiles and known profile of one constituent  
DeconRNASeq (Gong) [18] profiles of constituents  
Gong [19] cell-type specific gene signatures  
Abbas [20] cell-type specific gene signatures   
Wang M. [21] cell-type specific gene signatures 
Lu [22] cell-type specific gene signatures  *
PERT (Qiao) [46] reference profiles of constituents  † †  
ESTIMATE (Yoshihara) [47] prior data used to derive cell-type specific gene signatures   
DSection (Erkkilä) [12] prior knowledge of proportions †   
csSAM (Shen-Orr) [13] proportions of constituents    
Bar-Joseph [14] proportions of consitutents, one expression profile   
Ghosh [16] proportions, tumour & unmatched normal   *
Stuart [17] proportions of constitutents  
TEMT (Li) [48] prior knowledge of proportions, paired mixed-pure profiles  
DSA (Zhong) [23] cell markers     
ssNMF (Gaujoux) [25] cell markers    
PSEA (Kuhn) [24] cell markers    
deconf (Repsilber) [26] cell markers     
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Table 1 An overview of computational deconvolution algorithms for RNA profiles (Continued)
Tolliver [49] tumour profile, number of constituents   
Roy [50] prior estimate of number of constituents  
Lähdesmäki [15] mixed expression profiles † 
Venet [27] mixed expression profiles, number of constituents   
UNDO (Wang N.) [51] mixed expression profiles    
Most of the algorithms are applied to microarray mRNA abundance data, although TEMP and ESTIMATE use high-throughput RNA-Seq data and ISOpure and DeconRNASeq can be applied to both [52]. The possible outputs
of the algorithms are proportions of constituent cell-types (Prop.), average expression profiles (Expr.), or patient-specific expression profiles (Individual Profile) of constituent cell-types. The two main sources of clinical data
were cancer-related gene expression data (including human Hodgkin’s lymphomas) or normal blood expression data. PSEA was applied to expression data from patients with Huntington’s disease, and Bar-Joseph also
studied cell cycle synchronized foreskin fibroblast cells. In terms of availability, the summary package CellMix [28] is also an R package but is listed as a separate category. The only algorithms not available for either R or
MATLAB are PERT (Octave) and TEMT (Python). Algorithms which were described as using built-in MATLAB or R functions were not included, as reproducible example code is not available for them. The currently available
source code is summarized in Additional file 2.
Notes:
†Prior information about proportions or expressions is needed, but these values are re-estimated during the execution of the algorithm. For PERT, the individual profiles are adjusted (perturbed) versions of the reference
profiles.
*The original code for Lu (Java-based) [22] and Ghosh [16] is no longer available.
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αn represent the cancer fractions. The br and cn repre-
sent normal and purified cancer profiles, but they will be
interpreted as probabilities, as described in more detail
below. An overview of the algorithm workflow is given in
Figure 1.
While we focus on microarray mRNA abundance data,
ISOpure is generic when it comes to different species of
RNA. For example, it is able to deconvolve both mRNA
(non-coding RNAs inclusive) andmicroRNAs. This is true
for both microarray as well as next-generation sequenc-
ing (RNA-Seq) data. Input data matrices can represent
genes, isoforms, exons or microRNAs of samples. The
data matrices should represent approximate counts of
molecules (normalised but not log converted) for a given
RNA profile, e.g. gene level mRNA. However, the input
should not contain a mixture of mRNA and microRNA
data. ISOpure has been applied to the RNA-Seq The Can-
cer Genome Atlas (TCGA) PRAD dataset as part of that
project (manuscript in preparation), helping to demon-
strate its wider applicability.
The ISOpure statistical model
A more complete explanation of the statistical model is
given in the original article, [33], as well as in the ISOpureR
package vignette (Additional file 2). As noted, ISOpure
addresses the two-population problem, assuming that a
patient’s particular tumour mRNA abundance profile tn
can be decomposed into its cancer and healthy profile
components. For patient n,
tn = αncn + (1 − αn)hn + en. (2)
Here, cn is the personalized cancer profile, hn the profile
of the patient’s healthy tissue, αn the fraction of cancer
cells (0 ≤ αn ≤ 1) and en the reconstruction error.
This linear system of equations (for patients 1 to N) is
underdetermined, as the only known values are the tn’s. To
tumour profiles
normal profiles 
patient 
cancer profiles
Input
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, average cancer 
profile
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cancer per sample
•
•
• other parameters
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including patient healthy 
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•
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output
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Figure 1 ISOpure workflow. An overview of the ISOpure algorithm, illustrating the inputs and the most important outputs of the Cancer Profile
Estimation (CPE) and the Patient Profile Estimation (PPE) steps. The CPE step estimates an average cancer profile over all patients and the proportion
of cancer in each tumour, as well as the patient healthy profiles (as weights of input profiles). The healthy profile weights are re-estimated in the PPE
step. This second step estimates the purified cancer profile for each patient. All estimated parameters from the CPE and PPE steps are output by the
ISOpureR functions ISOpure.step1.CPE and ISOpure.step2.PPE.
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reduce the number of parameters to be estimated, as well
as to prevent overfitting, ISOpure employs two regulariza-
tion techniques. First, the patient-specific healthy profile,
hn is assumed to be a convex combination of a reference
set of known healthy profiles, b1, . . . ,bn:
tn = αncn +
R∑
r=1
θn,rbr + en (3)
where
αn +
R∑
r=1
θn,r = 1. (4)
This assumption is convenient for data availability (a
paired normal sample is not always available in archived
datasets), but is also motivated by biology; even a paired
healthy sample may not correspond exactly with the
healthy portion of the tumour sample, and may contain
noise. The second regularization assumption is that the
cancer profiles, cn cluster near an estimated reference can-
cer profile m, an assumption that is more accurate when
the cancers are all of the same subtype [34,35].
For the statistical model, the cancer profiles, m and cn,
and the healthy profiles, br , are transformed into proba-
bility distributions. Thus,
xˆn = αncn +
R∑
r=1
θn,rbr (5)
becomes a probability vector. The tumour sample tn is dis-
cretized to xn, and considered to be a sample from the
multinomial distribution with probability vector xˆn.
The following equations describe the full statistical
model, which is also illustrated in the Bayesian network
diagram in Additional file 3. To simplify notation, the
vector θn includes the entries θn,1, θn,2, . . . , θn,R,αn.
B = [b1, . . . ,bR] (6)
xˆn = [Bcn] θn (7)
p (xn|B, θn, cn) = Multinomial (xn|xˆn) (8)
p (θn|ν) = Dirichlet (θn|ν) (9)
p (cn|kn,m) = Dirichlet (cn|knm) (10)
p
(m|k′,B,ω) = Dirichlet (m|k′Bω) (11)
Equation (7) is simply Equation (5) in matrix form, and
Equation (8) summarizes the model described in the pre-
vious paragraphs.
The Dirichlet distributions are used for the parameters
θn,m and cn, which are discrete probability distributions.
The hyper-parameters ν, kn, k′ and ω determine the mean
and the concentration of the Dirichlet distributions.
The ISOpure algorithm
The goal of the algorithm is to maximize the complete
likelihood function
L = p (m|k′,B,ω)
N∏
n=1
p (cn|kn,m) p (θn|ν) p (xn|B, θn, cn).
(12)
The ISOpure algorithm splits this optimization into two
steps. The Bayesian diagram and the flowchart of the algo-
rithm for each step are given in Additional file 4. ISOpure
uses block coordinate descent where all variables except
one (or a ‘block’ of similar variables) are fixed, and the
objective is minimized with respect to the one variable (or
block).
Implementation
Motivation and software design
Themain contribution of this paper is the implementation
of ISOpure in the widely-used R statistical environment.
R is one of the most popular programming languages in
bioinformatics, in particular for the analysis and visualiza-
tion of genomic data. It is freely available under the GNU
General Public Licence (GPLv2/3) and can be extended by
many open-source packages.
ISOpure was originally implemented using MATLAB
[33,36]. The demand for an R version of ISOpure has
been motivated both by the cost-effectiveness of R, as well
as by the convenience and possible customization of the
algorithm in a familiar language. ISOpureR enables the
integration of the computational purification step within
existing data-analysis pipelines. The code was designed
using R version 3.1.1 (64-bit) on Ubuntu 12.04.4 LTS [37].
The organization of the R implementation closely fol-
lows the original MATLAB code. While the structure of
the code remains consistent, the advantage of using an
R package is that help files are easily accessible, as for
any package (e.g. typing help(package=ISOpureR)
after loading the library will list all functions). The most
important help file is the vignette (Additional file 2), which
gives details on the algorithm, the preprocessing steps
for microarray data and an extended example of run-
ning ISOpure on a computationally convenient dataset
included with ISOpureR, with visualizations of the output.
The internal test cases for the package also use this small
dataset to test the log likelihood and the derivative of the
log likelihood functions for each parameter.
Comparison with the original code
Two main challenges in the translation of ISOpure from
MATLAB to R were the differences in output of stan-
dard functions in the two languages, and differences in
running time. Surprisingly, MATLAB and R outputs dif-
fer for two of the most basic operators: greaterthan (>)
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and less than (<). In MATLAB, a comparison between
a number and NA or NaN returns FALSE, while in R
the output is NA. (For instance, 3 < NA would return 0
in MATLAB, and NA in R.) The optimization function
(ISOpure.model_optimize.cg_code.rminimize.R
in ISOpureR, which copies the MATLAB ISOpure func-
tion) performs a line search using quadratic and cubic
polynomial interpolations/extrapolations and the Wolfe-
Powell stopping criteria. Intermediate iterates which fall
outside the function’s domain result in infinite function or
derivative values, and NaN values in the succeeding iterate.
In this case, the ISOpure algorithm outputs FALSE when
testing the Wolfe-Powell stopping criteria and the search
continues with an adjusted search point. Thus, alterna-
tive versions of the greater and less than operators in
R (e.g. ISOpure.util.matlab_greater_than.R)
ensure the correct performance of the minimizing
function in ISOpureR.
Another difference in MATLAB and R is the behaviour
of the logarithm function for negative real values. In
R, log(x) outputs NaN for negative values of x, while
in MATLAB the output is a complex number. In order
to avoid underflow (the numerical error resulting from
computing a number too small in magnitude to store
in memory), ISOpure often performs calculations in the
log domain. For some of the intermediate calculations,
the logarithm of a negative value is calculated (e.g. the
logarithm of a derivative whichmay have negative compo-
nents).
In addition to code-level differences, R and MATLAB
differ in running time.MATLAB takes advantage ofmulti-
core processing by default. While the average elapsed time
for ISOpure in R was 1.73 to 2.61 times slower than
the CPU-time in MATLAB, it was much slower than
the elapsed time in MATLAB. To improve the runtime
of ISOpureR, the current version (v.1.0.16) incorporates
C++ code into the algorithm using RcppEigen [38], reduc-
ing the elapsed time two to three fold, from 8.9-13.4 to
3.9-4.8 times the elapsed MATLAB time. It is also use-
ful to note that despite the slower time, for running large
numbers of similar models (e.g. 50), the performance of
ISOpureR was faster overall, as the jobs could be submit-
ted simultaneously to a compute cluster, with no licence
limitations.
The size of the dataset influences runtime most signif-
icantly. The running time seems to be linearly dependent
on the number of transcripts/features when all other val-
ues (number of tumour samples, number of normal sam-
ples) are kept the same. Similarly, the time is also linearly
dependent on the number of tumour samples and normal
samples (Additional file 5).
Results and discussion
To verify the numerical equivalence of the MATLAB and
R implementations of ISOpure, their performances on
four datasets were compared. Two sets were of lung ade-
nocarcinoma from Bhattacharjee [39] and Beer [40] and
two were of prostate cancer from Wallace [41] and Wang
[42] (Table 2). These four datasets are among the tumour
datasets purified using ISOpure in [33], chosen because
the cancer types are not yet known to have established
subtypes. The array data processing was detailed in [33].
Each dataset was purified using both the MATLAB
and R implementations of ISOpure and we compared
the resulting parameters. The algorithms were run 50
times for each dataset, with different initial conditions. To
minimize differences due to random number generation
implementations, the initial values of parameters were
loaded from a file, and the extra optimizations of parame-
ters ν, ω, and k [33] in the CPE step, which included some
random initializations, were omitted. The results of these
models are very similar to results generated by the full,
randomized version of ISOpureR; the motivation for min-
imizing randomness was simply to reduce differences in
the performance comparisons between MATLAB and R.
The numerical differences in the parameter estimates
produced by MATLAB and R are small enough to have
no biological significance. We calculated the means of
the parameters (x¯MATLAB, x¯R, for each of the estimated
parameters such as ν,α, etc.) from the MATLAB and R
models over the 50 iterations. A comparison of the entries
of these mean parameter values produced by R and MAT-
LAB shows that the two implementations are numerically
analogous (Figure 2 and Additional file 6). In particular,
β1 and Spearman’s ρ are 1 for both the estimated frac-
tion of cancer cells in the tumour, α, and for the log of the
individual cancer profiles cn.
Table 2 An summary of the datasets used to validate ISOpureR
Dataset Ref. Cancer type Number of samples Number of transcripts
Tumour Normal
Beer [40] lung adenocarcinoma 86 10 5,151
Bhattacharjee [39] lung adenocarcinoma 139 17 8,383
Wallace [41] prostate cancer 69 18 12,140
Wang [42] prostate cancer 109 45 18,185
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Figure 2 A comparison of parameters estimated by the MATLAB and R implementations of ISOpure for the Beer dataset. Each plot shows the
entries of a parameter estimated using ISOpureR plotted against the corresponding entries estimated using the MATLAB code. The parameter is an
average over 49 models run with different initial conditions (one MATLAB model for the Beer dataset resulted in a zero θ value, and was dropped).
The line y = x is indicated in black, and the linear regression line, or robust regression line for θ , is dashed orange. (A) Parameters from the Cancer
Profile Estimation step of ISOpure: (i) ν , the hyper-parameter for the Dirichlet distribution over θ , (ii) θ , the proportion of a patient sample from a
known healthy-tissue profile, (iii)m, the average mRNA abundance cancer profile, (iv) α, the fraction of cancer cells for every patient sample, (v) ω a
hyper-parameter for the Dirichlet distribution overm. (B) Parameters from the Patient Profile Estimation step of ISOpure: (i) ν , the hyper-parameter
for the Dirichlet distribution over θ , (ii) θ , the proportion of a patient sample from a known healthy-tissue profile, (iii) cn , the purified mRNA
abundance cancer profile for each patient.
For the all datasets, the mean and median of the frac-
tional difference between the entries of the parameter
means are very close to zero for six of the nine param-
eters (Additional file 7). For instance, for both the Beer
and the Bhattacharjee datasets the means and medians
for the fractional difference of α and log cn are between
10−5 and 10−4. The three parameters having larger dif-
ferences, ω in the CPE step and θ in both CPE and PPE
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steps, contain very small entries which are not biologi-
cally significant. The entries of θ represent the weights of
known normal-tissue profiles adding up to a patient’s par-
ticular normal profile; a weight of 10−5 essentially means
that particular known normal profile is not present for
that patient. When entries larger than a certain thresh-
old, such as 10−5, are compared, the fractional difference
decreases.
Furthermore, the differences between the MATLAB
and R algorithms are similar to the differences within
each implementation, under different initial conditions
(Additional file 8). In particular, smaller numbers are not
as precisely predicted. Computationally, operations with
smaller numbers are susceptible to floating point round-
ing errors; however differences in small numbers do not
alter the model, as they are biologically unimportant.
Finally, the mean and median of the vector compo-
nents of (x¯MATLAB − x¯R) are very close to 0, and are
sometimes positive and sometimes negative. The R algo-
rithm does seem to under-estimate parameters compared
to MATLAB, but this bias disappears when we compare
parameter values larger than 10−5.
Conclusions
The first stage in the development of ISOpureR focused on
establishing the numerical equivalence of the results pro-
duced by the R and MATLAB code. Future steps include
testing backward compatibility with ISOLATE [43], the
precursor to ISOpure.
The translation of MATLAB code into R code was sur-
prisingly challenging. Debugging took five times as long as
the translation and initial testing, as differences in func-
tion performance appeared only for certain input values
during the execution of the full algorithm rather than in
the testing of individual functions. Perhaps some of the
differences in basic MATLAB and R operators mentioned
can be of help for others tackling a similar project. A list
of key issues encountered is in Additional file 9.
One of the recommendations for the comparison of
implementations would be to eliminate all sources of
randomness in the algorithms and postpone the improve-
ment of running time only once numerical results are
consistent, and consistently reproducible given different
initial random seeds.
Most importantly, the contribution of the R implemen-
tation of the ISOpure algorithm is that it can now be
readily integrated into existing analysis pipelines. ISOp-
ureR can easily be included in benchmark comparisons of
different deconvolution algorithms. A promising upcom-
ing project is the ICGC-TCGA DREAM Somatic Muta-
tion Calling - Tumour Heterogeneity Challenge [44], a
benchmarking competition of computational methods
for determining the best sub-clonal reconstruction algo-
rithms. The collaborative-competitive framework of the
DREAM projects encourages transparency in algorithm
development and the availability of open-source code.
The R implementation of ISOpure provides increased
flexibility and ease of parallelization, so that the algo-
rithm may be easily modified, extended and tested by the
community.
Availability and Requirements
The ISOpureR package is submitted to the Comprehensive
R Archive Network (CRAN) which maintains an active
package homepage for ISOpureR. The version of the code
at the time of publication is included in Additional file 10.
The package is written an implemented in the R program-
ming language (version ≥ 3.1.1), with some C++ code
incorporated using Rcpp [45] and RcppEigen [38]. It is
platform-independent, but has been primarily tested on
Linux, and is available under the GLP-2 license.
Additional files
Additional file 1: (Table) A summary of software availability for
deconvolution ofmRNAabunance data. A similar table is given in [52].
Additional file 2: The vignette of the ISOpureR package,
ISOpureRGuide.pdf, including an extended description of the
ISOpure model and algorithm, preprocessing steps for microarray
files, and examples for applying ISOpureR to datasets. This file is also
found within the ISOpureR package, in Additional file 10.
Additional file 3: (Figure) Bayesian network model for the ISOpure
statistical model.
Additional file 4: (Figures) Bayesian network and flowchart diagrams
for the cancer profile estimation and patient profile estimation steps
of the ISOpure algorithm.
Additional file 5: (Figures) A comparison of running time for
different dataset sizes (different number of transcripts or different
number of tumour samples).
Additional file 6: (Figures) A comparison of parameters estimated by
the MATLAB and R implementations of ISOpure for the
Bhattacharjee, Wallace, andWang datasets.
Additional file 7: (Tables) Statistics for differences in parameters
estimated by the MATLAB and R implementations of ISOpure for the
Beer, Bhattacharjee, Wallace, andWang datasets.
Additional file 8: (Figure) A comparison of the parameter estimation
in models with different initial conditions, one programming
language.
Additional file 9: Recommendations for translating code from
MATLAB to R.
Additional file 10: ISOpureR R package as a Linux-compatible file.
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